| Oral iron use, by DOPPS country and cross-section |
| N Ptnts | Total N | Wgtd % | ||
|---|---|---|---|---|
| DOPPS Country | DOPPS Cross-section | 66 | 506 | 12.4% |
| AusNZ | D2(2002) | |||
| D3(2006) | 33 | 448 | 8.2% | |
| D3(2007) | 40 | 445 | 8.8% | |
| D4(2010) | 1 | 326 | 0.3% | |
| Belgium | D2(2002) | 14 | 534 | 2.6% |
| D3(2006) | 1 | 479 | 0.2% | |
| D3(2007) | 2 | 367 | 0.4% | |
| D4(2010) | 1 | 396 | 0.2% | |
| Canada | D2(2002) | 114 | 576 | 22.4% |
| D3(2006) | 83 | 508 | 22.1% | |
| D3(2007) | 66 | 420 | 23.4% | |
| D4(2010) | 33 | 333 | 14.5% | |
| France | D2(2002) | 10 | 499 | 2.8% |
| D3(2006) | 96 | 540 | 16.3% | |
| D3(2007) | 137 | 539 | 25.4% | |
| D4(2010) | 1 | 345 | 0.3% | |
| Germany | D2(2002) | 15 | 565 | 2.5% |
| D3(2006) | 35 | 555 | 6.2% | |
| D3(2007) | 40 | 606 | 6.0% | |
| D4(2010) | 1 | 567 | 0.1% | |
| Italy | D2(2002) | 10 | 555 | 1.8% |
| D3(2006) | 109 | 500 | 21.4% | |
| D3(2007) | 119 | 506 | 26.4% | |
| Japan | D2(2002) | 51 | 1,720 | 3.0% |
| D3(2006) | 63 | 1,759 | 3.2% | |
| D3(2007) | 61 | 1,783 | 3.1% | |
| D4(2010) | 32 | 1,694 | 1.8% | |
| Spain | D2(2002) | 26 | 595 | 3.7% |
| D3(2006) | 10 | 620 | 1.6% | |
| D3(2007) | 11 | 529 | 2.6% | |
| Sweden | D2(2002) | 32 | 545 | 6.3% |
| D3(2006) | 133 | 504 | 24.2% | |
| D3(2007) | 118 | 493 | 23.7% | |
| D4(2010) | 1 | 471 | 0.3% | |
| UK | D2(2002) | 25 | 543 | 4.4% |
| D3(2006) | 46 | 431 | 11.5% | |
| D3(2007) | 40 | 325 | 13.7% | |
| D4(2010) | 3 | 386 | 0.9% | |
| US | D2(2002) | 270 | 2,156 | 12.7% |
| D3(2006) | 71 | 1,735 | 4.9% | |
| D3(2007) | 58 | 1,162 | 5.4% | |
| D4(2010) | 130 | 3,063 | 4.6% | |
| Medications reported as prescribed (not necessarily taken) in previous four months, among all patients |
Please see additional methodological information in the Data Sources and Methods section.